Ono Pharmaceutical Co. Ltd. has entered its second agreement this year with a Switzerland-based biotech developing novel antibodies, as it bulks up its research effort fired by the success of the checkpoint inhibitor Opdivo (nivolumab), developed in collaboration with partner Bristol-Myers Squibb Co.
This time the Japanese company has forged a collaboration with Neurimmune Holdings AG, a Zurich-based firm, which will generate...








